Challenging ourselves to look at the market from different angles, including ensuring that the clinical needs of the patient in the real-world are understood, is of paramount importance for Mundipharma. It is only with this clear insight that we can continue to help define, develop and deliver leading innovations in medicine.

Kate Hurtig, Head of Pain
 

Products

Over the past 50 years, the network of Mundipharma independent associated companies has established their expertise in pain and expanded their research and development capabilities into a number of other therapeutic areas.

The current product range detailed below varies from country to country depending on market authorisations.


Trade name Generic name Therapy area Countries availability
 Remsima®▼    infliximab Rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and paediatric Crohn’s disease, ulcerative colitis and paediatric ulcerative colitis, psoriasis and psoriatic arthritis Belgium, Germany, Italy, Luxembourg, Netherlands, UK

Remsima is also approved for use in other countries where Mundipharma does not have rights to the product
flutiform▼®
flutiformo®
fluticasone propionate / formoterol Asthma Australia, Belgium, Bulgaria, Cyprus, Czech Republic, France, Denmark, Finland, Germany, Hong-Kong, Iceland, Ireland, Israel, Italy, Luxemburg, Netherlands, Norway, Slovakia, South Korea, Sweden, Switzerland, UK

fluticasone proprionate/formoterol is also approved for use in other countries where Mundipharma does not control rights to the product
Levact▼®
Ribomustin®
Ribovact®
bendamustine hydrochloride  Haematological malignancies Approved for use in the following Mundipharma territories: Austria, Belgium, Bulgaria, Denmark, Cyprus, Czech Republic, Finland, France, Germany, Iceland, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the UK

Bendamustine hydrochloride is also approved for use in other countries where Mundipharma does not control rights to the product
DepoCyte® cytarabine Haematological malignancies Approved for use in the following Mundipharma territories: South Korea, Switzerland and throughout the European Union

Cytarabine is also approved for use in other countries where Mundipharma does not control rights to the product
Folotyn® pralatrexate Haematological malignancies Approved for use in the following Mundipharma territories: Israel and South Korea

Folotyn® is undergoing regulatory assessment in a number of Mundipharma territories including Asia, Australasia, Latin America and other Middle Eastern countries

Pralatrexate is also approved for use in other countries where Mundipharma does not control rights to the product
BuTrans®
Norspan®
buprenorphine Pain Denmark, Finland, Ireland, Netherlands, Norway, Sweden, UK

Buprenorphine patch is also approved for use in other countries where Mundipharma does not control rights to the product
MST® Continus® morphine sulphate (prolonged release) Pain Austria, Belgium, Bulgaria, Croatia, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Romania, Slovakia, Spain, Switzerland, UK
Palladon®
Palladone®
Hydal®
hydromorphone (immediate release) Pain Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, Netherlands, Norway, Sweden, Switzerland, UK
Palladon®
Palladone®
Hydal®
hydromorphone injection Pain Austria, Belgium, Denmark, Germany, Luxembourg, Sweden, Switzerland
Palladon®
Palladone®
Hydal®
Sophidone®
hydromorphone (prolonged release) Pain Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Luxembourg, Netherlands, Norway, Spain, Slovakia, Slovenia, Sweden, Switzerland, UK
OxyNorm® oxycodone (immediate release) Pain Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK
OxyContin® OxyGesic® oxycodone (prolonged release) Pain Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Denmark, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK
Targin®
Targinact▼®
Targiniq®
oxycodone
naloxone
Pain European Union & Switzerland
Lodotra® modified-release prednisone Rheumatoid arthritis Austria, Belgium, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Netherlands, Norway, Poland, Sweden, Switzerland, UK

Please refer to individual countries for full product indication, and local prescribing information.

Our associate network is actively involved in four therapeutic areas: